Interesting ImagesPeptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide TherapyZhang, Jingjing MD, PhD; Kulkarni, Harshad R. MD; Baum, Richard P. MD, PhDAuthor Information From the THERANOSTICS Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Bad Berka, Germany. Received for publication September 27, 2019; revision accepted November 2, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Jingjing Zhang, MD, PhD, THERANOSTICS Center for Molecular, Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437, Bad Berka, Germany. E-mail: firstname.lastname@example.org. Online date: January 30, 2019 Clinical Nuclear Medicine: March 2020 - Volume 45 - Issue 3 - p 241-243 doi: 10.1097/RLU.0000000000002915 Buy Metrics Abstract We present here a case with β-radiation–refractory metastatic neuroendocrine tumors, who demonstrated an excellent therapy response after 1 cycle of 225Ac-DOTATOC, without any significant adverse effects even after 10 cycles of β-emitter peptide receptor radionuclide therapy followed by α-peptide receptor radionuclide therapy. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.